Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
Solomon Tesfaye,Andrew J.M. Boulton,Peter J. Dyck,Roy Freeman,Michael Horowitz,Péter Kempler,Giuseppe Lauria,Rayaz A. Malik,Vincenza Spallone,Aaron I. Vinik,Luciano Bernardi,Paul Valensi +11 more
TL;DR: A joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium on Diabetes in Toronto, Canada, 13-18 October 2009, expert panels were convened to provide updates on classification, definitions, diagnostic criteria, and treatments of diabetic peripheral neuropathies as mentioned in this paper.
read more
Abstract: Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium on Diabetic Neuropathy in Toronto, Canada, 13-18 October 2009, expert panels were convened to provide updates on classification, definitions, diagnostic criteria, and treatments of diabetic peripheral neuropathies (DPNs), autonomic neuropathy, painful DPNs, and structural alterations in DPNs.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
•Journal Article
High dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments: results of a double blind, randomized, placebo-controlled, multicenter trial
Luisa De Toni Franceschini,Raffaella Fazio,Dario Cocito,A. Toscano,A Schenone,G Marfia,Giovanni Antonini,Anna Mazzeo,Marina Grandis,Daniele Velardo,Giorgia Mataluni,Erdita Peci,S. Jann +12 more
TL;DR: Treatment with IVIG at the dose given was efficacious and safe for patients with DPN resistant to standard therapies and achieved its prespecified primary end point of ≥50% pain reduction at four weeks after IVIG.
10
•Dissertation
HDL functionality and lipoprotein quality in diabetes mellitus
Jonathan Schofield
- 01 Jan 2017
TL;DR: This paper presents a meta-analysis of how HDL Protects against Atherogenic Modification and its effects on Lipoprotein Cholesterol Raising and the Contribution of Copper.
10
Sensory profile and its impact on quality of life in patients with painful diabetic polyneuropathy.
TL;DR: PDN significantly affects patients’ quality of life, especially physical function and role limitation due to a physical problem, and physical functioning was the most affected and social function was the least affected.
10
Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study
TL;DR: Over 3 years period, SGLT2i significantly improved some neuropathy outcome measures, mean Z-score of 8 neurophysiological tests, and attenuated nephropathy in modestly controlled type 2 diabetes by reducing glycemic variability and mean nonglycemic factors of diabetic microvascular complication.
Serum Uric Acid Levels Are Related to Diabetic Peripheral Neuropathy, Especially for Motor Conduction Velocity of Tibial Nerve in Type 2 Diabetes Mellitus Patients
Huina Zhang,Carvalho Vladmir,Zhenyu Zhang,Wan-xing Zhou,Jiang Xu,Yang Chen,Mengting He,Ya Zhang,Wei Wang,Haoqiang Zhang +9 more
TL;DR: In this paper , the role of serum uric acid (SUA) in the DPN of patients with type 2 diabetes mellitus (T2DM) was determined and correlation and regression analyses were performed to explore the association between SUA and DPN.
References
Neuropathic pain Redefinition and a grading system for clinical and research purposes
Rolf-Detlef Treede,Troels S. Jensen,James N. Campbell,Giorgio Cruccu,Jonathan O. Dostrovsky,J. W. Griffin,Per Hansson,Richard A. C. Hughes,Turo Nurmikko,Jordi Serra +9 more
TL;DR: A grading system of definite, probable, and possible neuropathic pain is proposed, which includes the grade possible, which can only be regarded as a working hypothesis, and the grades probable and definite, which require confirmatory evidence from a neurologic examination.
2.5K
Diabetic neuropathies: a statement by the American Diabetes Association.
Andrew J.M. Boulton,Andrew J.M. Boulton,Arthur I. Vinik,Joseph C. Arezzo,Vera Bril,Eva L. Feldman,Roy Freeman,Rayaz A. Malik,Raelene E. Maser,Jay M. Sosenko,Dan Ziegler +10 more
TL;DR: Not all patients with peripheral nerve dysfunction have a neuropathy caused by diabetes, and effective symptomatic treatments are available for the manifestations of DPN and autonomic neuropathy.
Neuropathic pain: redefinition and a grading system for clinical and research purposes.
TL;DR: The clinical resemblance between patients with and without evidence of disease has been taken to indicate that both profiles are neuropathic, but the second profile is not.
1.3K
Diabetic Cardiovascular Autonomic Neuropathy
Aaron I. Vinik,Dan Ziegler +1 more
TL;DR: The present report discusses the clinical manifestations (eg, resting tachycardia, orthostasis, exercise intolerance, intraoperative cardiovascular liability, silent myocardial infarction [MI], and increased risk of mortality), and demonstrates that autonomic dysfunction can affect daily activities of individuals with diabetes and may invoke potentially life-threatening outcomes.
1.2K
Vascular risk factors and diabetic neuropathy
Solomon Tesfaye,Nish Chaturvedi,Simon E.M Eaton,John D. Ward,Christos Manes,Constantin Ionescu-Tirgoviste,Daniel R. Witte,John H. Fuller +7 more
TL;DR: It is indicated that, apart from glycemic control, the incidence of neuropathy is associated with potentially modifiable cardiovascular risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension.